摘要
新型冠状病毒诱导的原发免疫性血小板减少症(SARS-CoV-2-induced ITP)是一种继发于病毒感染的自身免疫性疾病。该病主要通过排除法诊断,需检测凝血四项、血小板生成素、药物依赖性抗体等指标,与其他导致血小板数降低的诱因鉴别后谨慎诊断。如何平衡出血与血栓风险,制定个体化给药方案是该病治疗的重点与难点。由于血小板生成素受体激动剂(TPO-RA)存在加速血栓形成的副作用,可能加重患者肺栓塞症状,因此仅用于难治性SARS-CoV-2-induced ITP患者。本文就SARS-CoV-2-induced ITP的发病机制、诊断及治疗方案的最新研究进展作一综述。
SARS-CoV-2-induced immune thrombocytopenia(SARS-CoV-2-induced ITP)is an autoimmune disease secondary to virus infections.Its diagnosis is often based on exclusion of other possible causes of thrombocytopenia in COVID-19 patients.Common laboratory examinations include coagulation function,thrombopoietin and drug-dependent antibodies.Since both bleeding and thrombosis risks are seen in SARS-CoV-2-induced ITP patients,individual remedy is essential for the treatment of this disease.Because thrombopoietin receptor agonist(TPO-RA)has the side effect of accelerating thrombosis and may aggravate the pulmonary embolism symptoms of patients,it should be used for refractory SARS-CoV-2-induced ITP patients only.This review briefly summarizes the recent research progress in the pathogenesis,diagnosis and treatment of SARS-CoV-2-induced ITP.
作者
周心蕙
阮长耿
何杨
ZHOU Xin-Hui;RUAN Chang-Geng;HE Yang(Department of Thrombosis and Hemostasis,The First Affiliated Hospital of Soochow University,Jiangsu Institute of Hematology,Suzhou 215006,Jiangsu Province,China)
出处
《中国实验血液学杂志》
CAS
CSCD
北大核心
2023年第2期593-597,共5页
Journal of Experimental Hematology
